Phase I-II trial of cisplatin, vinblastine, and methylgluoxal-bis (guanylhydrazone) (MGBG)...
1
138 ring were moderate and severe in patients with CAP and PP. Other toxicity was mild " and moderate and there was no drug related deaths. Vindesine (VDS) Sensitivity Testing on Htunan Lung Cancer Biopsies by Fast-Green-Assay (FGA) .~omparison With T~eatment Results2 Postmus , ~.E., de Vries , E.G.E., Meyer , J., Mulder , N.H. Departments of i. Pulmo- nary Diseases, 2. Medical Oncology. State University, Groningen, The Netherlands. Selection of responders by in vitro screening of drug sensitivity on tumor biopsies would improve treatment results in patients with lung cancer. Non-surgical biopsies in such patients are too small for clonogenic assay (CA). Comparison of the results of CA and FGA (Cancer Research 1983; 43: 258) in 4 human lung tumor cell lines indicated a parallel dose response relationship for VDA and requirement of less tumor cells for FGA. The effect of VDS was evaluated on 64 lung tumor biopsies by FGA. 48 biopsies were taken by rigid bronchoscopy, 12 sur- gical biopsies from primaries or lymph no- des and 4 aspirates (3 pleural effusion, 1 bone marrow). The number of cells was in 25_bronchoscopy biopsies sufficient (> 2 x l0 b ) to perform a test, 3 failed due to contamination, in i0 all cells in the con- trol were dead and in 12 cases an evaluable results was obtained. Of the 16 other speci- mens ii were evaluable. In 5 out of 23 a > 70% reduction of ~he cell number was seen. VDS (1.75 mg/m-) was given biweekly for 2 weeks with 2 weeks interval to 26 pa- tients (14 SCLC, 3 adeno, 1 adeno-squamous, 8 squamous). 5 PR, 2 MR were seen. 2 pa- tients had neurotoxicity grade 3-4, i0 grade 1 after 2 wks. Myelotoxicity was nor- mal. Conclusions: 1 FGA is comparable to CA, but requires less tumor cells. 2 FGA is_possible on biopsies containing > 2 x b i0 cells. Bronchoscopic biopsies will give an evaluable result in 25% of the ca- ses. 3 overall activity of VDS in FGA and in patients is comparable. Pilot Study on the Use of Adjuvant Combi- nation Chemotherapy in the ~nagement of Small - Cell Carcinoma of the Bronchus. Ai-Niaimi, A.S. Medical College Baghdad University, Baghdad, Iraq. 40 patients with histologically proven diagnosis were treated by local irradia- tion together with combination chemothe- rapy. There were 36 males and 4 females. Chemo- therapy consisted of cyclophosphamide, a- driamycin, vincristine and methotrexate. There were 8 complete responses, ii partial responses and 21 with no response. The overall response rate of 47.5%. Re- sponders lived for an average of 8.2 months in comparison with 2 months for non-responders. Phase I-II Trial of Cisplatin, Vinblastine, and Methylgluoxal-Bis (Guanylhydrazone) (MGBG) Combination Chemotherapy in Non-Small Cell Lung Cancer. Chapman, R.A., O'Bryan, R.M., Talley, R.W., Tilchen, E.J. Henry Ford Hospital, Detroit, Michigan, U.S.A. The combination of cisplatin (DDP) and vin- blastine (VBL) has had demonstrable efficacy in several studies. As a single agent, in non-previously treated patients MGBG has had moderate activity without significant myelo- toxicity. We added MGBG to DDP and VBL in se- veral dosage schedules in an effort to improve upon the response rate and overall survival. The dose of MGBG ranged from 400-500 mg/m 2 given everY214 days. DDP was administered at 80-120 mg/m day i, 29 and every 6 weeks?there- after. The VBL dose ranged from 2-3 mg/m- day i, 2, 15, 16, 29, 30 and every 3 weeks there- after. All 37 patients entered into the trial had measurable, metastatic, non-small cell lung cancer, and no prior chemotherapy. Median Karnofsky performance status was 70 (range 40- i00), median age was 60 (range 36-78). 19% patients had epidermoid carcinoma. 62% patients had adenocarcinoma, 15% patients had large cell carcinoma, and 1 patient (3%) had mixed histo- logy. Myelosuppression wa~ moderate to severe (median WBC nadir 1700/mm-) at the highest dose level. One patient had significant ne- phrotoxicity. 15 of 31 (48%) evaluable patients responded to therapy. Responders included 9/18 patients with adenocarcinoma, 2/6 patients with epidermoid carcinoma, 2/6 patients with large cell carcinoma, and i/i patient with mixed (adeno and epidermoid) histology. Overall survival has been I0 months, and the median survival of responders has not been reached at 14+ months. We conclude that DDP, MGBG, and VBL is an active regimen in patients with metastatic non-small cell lung cancer, and deserves further study. Comparison Between High Doses-Cisplatin and Low Doses Cisplatin in Combined Chemotherapy With VP-16 For Advanced NSCLC. Salvati, F., Cruciani, A.R., Antilli, A., Mugnaini, L., Orazi, D., Signora, M., Portalo- ne, L., Nunziati, F. 8th Dept. Pneumology "Forlanini" Hospital, 00149 Rome, Italy. High doses of cisplatin have been found to result in better effectiveness than low doses (Ann Intern Med 95, 414, 1981) in treat- ment of NSCLC. Therefore ~e compared the effi- cacy of cispla~in 60 mg/m i.v. day 1 plus VP-16 120 mg/m- i.v. day 2, 3, 4 in 45 pts with NSCLC stage III M -M~ versus the effi- cacy of cisplatin i9 l~0 ~g/m z i.v. day 1 plus VP-16 120 mg/m- i.v. day 2, 3, 4 in 33 pts with NSCLC stage III Mo?M I. The median age of pts of the first serles resulted in 57
Transcript of Phase I-II trial of cisplatin, vinblastine, and methylgluoxal-bis (guanylhydrazone) (MGBG)...
138
ring were moderate and severe in patients with CAP and PP. Other toxicity was mild "
and moderate and there was no drug related deaths.
Vindesine (VDS) Sensitivity Testing on Htunan Lung Cancer Biopsies by Fast-Green-Assay (FGA) .~omparison With T~eatment Results2 Postmus , ~.E., de Vries , E.G.E., Meyer , J., Mulder , N.H. Departments of i. Pulmo- nary Diseases, 2. Medical Oncology. State University, Groningen, The Netherlands.
Selection of responders by in vitro screening of drug sensitivity on tumor biopsies would improve treatment results in patients with lung cancer. Non-surgical biopsies in such patients are too small for clonogenic assay (CA). Comparison of the results of CA and FGA (Cancer Research 1983; 43: 258) in 4 human lung tumor cell lines indicated a parallel dose response relationship for VDA and requirement of less tumor cells for FGA.
The effect of VDS was evaluated on 64 lung tumor biopsies by FGA. 48 biopsies were taken by rigid bronchoscopy, 12 sur- gical biopsies from primaries or lymph no- des and 4 aspirates (3 pleural effusion, 1 bone marrow). The number of cells was in 25_bronchoscopy biopsies sufficient (> 2 x l0 b ) to perform a test, 3 failed due to contamination, in i0 all cells in the con- trol were dead and in 12 cases an evaluable results was obtained. Of the 16 other speci- mens ii were evaluable. In 5 out of 23 a > 70% reduction of ~he cell number was seen.
VDS (1.75 mg/m-) was given biweekly for 2 weeks with 2 weeks interval to 26 pa- tients (14 SCLC, 3 adeno, 1 adeno-squamous, 8 squamous). 5 PR, 2 MR were seen. 2 pa- tients had neurotoxicity grade 3-4, i0 grade 1 after 2 wks. Myelotoxicity was nor- mal.
Conclusions: 1 FGA is comparable to CA, but requires less tumor cells. 2 FGA is_possible on biopsies containing > 2 x
b i0 cells. Bronchoscopic biopsies will give an evaluable result in 25% of the ca- ses. 3 overall activity of VDS in FGA and in patients is comparable.
Pilot Study on the Use of Adjuvant Combi- nation Chemotherapy in the ~nagement of Small - Cell Carcinoma of the Bronchus. Ai-Niaimi, A.S. Medical College Baghdad University, Baghdad, Iraq.
40 patients with histologically proven diagnosis were treated by local irradia- tion together with combination chemothe- rapy.
There were 36 males and 4 females. Chemo- therapy consisted of cyclophosphamide, a- driamycin, vincristine and methotrexate. There were 8 complete responses, ii partial responses and 21 with no response.
The overall response rate of 47.5%. Re-
sponders lived for an average of 8.2 months in comparison with 2 months for non-responders.
Phase I-II Trial of Cisplatin, Vinblastine, and Methylgluoxal-Bis (Guanylhydrazone) (MGBG) Combination Chemotherapy in Non-Small Cell Lung Cancer. Chapman, R.A., O'Bryan, R.M., Talley, R.W., Tilchen, E.J. Henry Ford Hospital, Detroit, Michigan, U.S.A.
The combination of cisplatin (DDP) and vin- blastine (VBL) has had demonstrable efficacy in several studies. As a single agent, in non-previously treated patients MGBG has had moderate activity without significant myelo- toxicity. We added MGBG to DDP and VBL in se- veral dosage schedules in an effort to improve upon the response rate and overall survival.
The dose of MGBG ranged from 400-500 mg/m 2 given everY214 days. DDP was administered at 80-120 mg/m day i, 29 and every 6 weeks?there- after. The VBL dose ranged from 2-3 mg/m- day i, 2, 15, 16, 29, 30 and every 3 weeks there- after. All 37 patients entered into the trial had measurable, metastatic, non-small cell lung cancer, and no prior chemotherapy. Median Karnofsky performance status was 70 (range 40- i00), median age was 60 (range 36-78). 19% patients had epidermoid carcinoma. 62% patients had adenocarcinoma, 15% patients had large cell carcinoma, and 1 patient (3%) had mixed histo- logy. Myelosuppression wa~ moderate to severe (median WBC nadir 1700/mm-) at the highest dose level. One patient had significant ne- phrotoxicity. 15 of 31 (48%) evaluable patients responded to therapy. Responders included 9/18 patients with adenocarcinoma, 2/6 patients with epidermoid carcinoma, 2/6 patients with large cell carcinoma, and i/i patient with mixed (adeno and epidermoid) histology. Overall survival has been I0 months, and the median survival of responders has not been reached at 14+ months.
We conclude that DDP, MGBG, and VBL is an active regimen in patients with metastatic non-small cell lung cancer, and deserves further study.
Comparison Between High Doses-Cisplatin and Low Doses Cisplatin in Combined Chemotherapy With VP-16 For Advanced NSCLC. Salvati, F., Cruciani, A.R., Antilli, A., Mugnaini, L., Orazi, D., Signora, M., Portalo- ne, L., Nunziati, F. 8th Dept. Pneumology "Forlanini" Hospital, 00149 Rome, Italy.
High doses of cisplatin have been found to result in better effectiveness than low doses (Ann Intern Med 95, 414, 1981) in treat- ment of NSCLC. Therefore ~e compared the effi- cacy of cispla~in 60 mg/m i.v. day 1 plus VP-16 120 mg/m- i.v. day 2, 3, 4 in 45 pts with NSCLC stage III M -M~ versus the effi- cacy of cisplatin i 9 l~0 ~g/m z i.v. day 1 plus VP-16 120 mg/m- i.v. day 2, 3, 4 in 33 pts with NSCLC stage III Mo?M I. The median age of pts of the first serles resulted in 57
